Company intelligence / Profile preview

iXgene Inc.

Shinjuku-ku, Tokyo, Japanixgene.inc ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has published research on gene-cell therapy for glioblastoma using suicide gene-transfected iPS cell-derived neural stem cells and on neuroprotective effects of genome-edited iPS cell-derived neural stem cells in traumatic brain injury.

Therapeutic areas: OncologyNeurology
Modalities: Gene-cell therapygenome-edited iPS cells
Industry: Biotech

Drug pipeline

1 asset

iXgene iPS cell-derived neural stem cell therapy

Unknown

Partnerships

Sumitomo PharmaC4UKeio University

Beyond the preview

Go deeper on iXgene Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iXgene Inc..

Explore the full profile